Interferon beta-1a - Merck Serono

Drug Profile

Interferon beta-1a - Merck Serono

Alternative Names: r-IFNβ-1a; Rebif; Rebif Rebidose; Rebif® modified formulation; Rebif® New Formulation; Rebif® reformulation; Rebif® Serum-free formulation; Recombinant human interferon beta-1a; RNF - Merck Serono

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Weizmann Institute of Science
  • Developer EMD Serono; Merck Serono
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis
  • No development reported Hepatitis C; Human papillomavirus infections; Non-small cell lung cancer; Ulcerative colitis
  • Discontinued Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2014 Biomarkers information updated
  • 06 May 2014 EMD Serono plans a phase IV RESOunD trial for Multiple Sclerosis in USA (NCT02117050)
  • 01 Sep 2013 Merck completes the global phase III REFLEXION extension trial for Multiple sclerosis (NCT00813709)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top